PPT-UCART20X22: ALLOGENEIC DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES

June 2 nd 2023 Roman Galetto PhD Preclinical Vice President ForwardLooking Statements This presentation contains forwardlooking statements within the meaning of applicable securities laws including the Private Securities Litigation Reform Act of 1995 Forwardlooking statements may be identified by words such as designed to anticipate expected on track plan scheduled should and will or the negative of these and similar expressions . Learning Goals. Immunotherapies in B-Cell Malignancies. Available Immunotherapies. OS in MM. Poor Outcome in High-Risk Myeloma. Immunotherapy. Potential for Success Without a Targetable Molecular Mutation. Hematopoietic. stem cell. Neutrophils. Eosinophils. Basophils. Monocytes. Platelets. Red cells. Myeloid. progenitor. Lymphoid. progenitor. B-lymphocytes. T-lymphocytes. Plasma. cells. germinal center. Rouslan Kotchetkov. ,. MD, PhD. 1. , Erin Ellison, MD. 2. , . McLean J, PhD. 1. , Bryn . Pressnail, MD. 1. , Derek Nay, MD. 1. .  . 1. Simcoe . Muskoka. Regional Cancer Program. , . 2. Department . Hematopoietic. stem cell. Neutrophils. Eosinophils. Basophils. Monocytes. Platelets. Red cells. Myeloid. progenitor. Lymphoid. progenitor. B-lymphocytes. T-lymphocytes. Plasma. cells. germinal center. haematological. malignancies. Ass.Prof.Abeer. . Anwer. Ahmed. The . aetiology. of . haemopoietic. malignancy. Cancer . results from the accumulation of genetic mutations. within a cell and the number present varies widely from over. June 28, 2018. Management of hematologic malignancies in older patients. Disclosures. for Tanya Wildes. Honorarium. Carevive. Systems. Research Funding. Janssen. Key issues (1). Are the considerations in older adults with hematologic malignancies different than in solid tumors?. By Brandy Sargent Editor, Cell Culture Dish www.cellculturedish.com Recently, the Pharmaceutical Research and Manufacturers of America released a report “ Medicines in Development – Biologics, 2 Information for young people with cancer, and parents of a child or young person with cancer, having a donor (allogeneic) stem cell transplantGraft versus host disease (GvHD) www.cclg.org.ukstem cell Mohammed A. Suwaid, MD. Board-certified Medical Oncologist. Anbar Cancer Center. AGENDA. Cancer . Oncology. Role of MDT in managing cancer. Surgical treatment. Radiation treatment. Systemic treatment. October 19, 2019. Process of Hematopoietic Stem Cell Transplantation. “conditioning”- high doses of chemotherapy .  total body radiation to kill all the bone marrow. Stem cells are then infused to salvage marrow function. Georgette A. Dent, MD. University of North Carolina School of Medicine. Objectives. To review normal peripheral blood, bone marrow, and lymph node pathology. To briefly review the categories of treatment used to treat these malignancies. Otto Visser. June 2019. Coding issues. Introduction. For most (solid) cancers, the primary site of the most important factor for the prognosis and the choice of treatment. For other cancers, especially haematological malignancies, but also for an increasing number of solid cancers, the morphological classification is the most important factor. Myeloid. Lymphoid. Histiocytic. Myeloid . neoplasms. (1) . Myeloproliferative. . neoplasms. (2) . Myelodysplastic. syndromes. (3) Acute myeloid leukemia. Features:. Recurrent genetic mutations. Increased bone marrow cellularity. +. Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE-203). Alison Moskowitz. 1. , Andreas Harstrick. 2. , Michael Emig. 2. , Andre Overesch. 2. ,. . Sheena Pinto. 2. , . Paulien Ravenstijn. 2.